Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on March 5, 2019. The filing announces the financial results for the fourth quarter and the full fiscal year ended December 31, 2018. The company is an emerging growth company based in Cincinnati, Ohio.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not detail specific material changes versus the prior comparable period. It serves solely as a notification that the results for the period ended December 31, 2018, have been announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is Aerpio Pharmaceuticals, Inc., as the input metadata incorrectly listed Whitehawk Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for Q4 and FY 2018.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the financial data in this 8-K is not incorporated by reference into other filings unless specifically cited.